Parameters influencing renal response to SGLT2 inhibitors and GLP1 receptor agonists in type 2 diabetes patients with preserved renal function: a comparative, prospective study

Perkovic V, Jardine MJ, Neal B, CREDENCE Trial Investigators et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380(24):2295–2306. https://doi.org/10.1056/NEJMoa1811744

Article  PubMed  CAS  Google Scholar 

Salah HM, Al’Aref SJ, Khan MS et al (2021) Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update. Am Heart J 233:86–91. https://doi.org/10.1016/j.ahj.2020.12.007

Article  PubMed  CAS  Google Scholar 

Kristensen SL, Rørth R, Jhund PS et al (2019) Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 7:776–785. https://doi.org/10.1016/S2213-8587(19)30249-9.Erratum.In:(2020)LancetDiabetesEndocrinol8:e2

Article  PubMed  CAS  Google Scholar 

Tricò D, Solini A (2021) Glucagon-Like Peptide-1 Receptor Agonists-Use in Clinical Practice. Adv Chronic Kidney Dis 28:328–336. https://doi.org/10.1053/j.ackd.2021.04.002

Article  PubMed  Google Scholar 

Heerspink HJL, Stefánsson BV, Correa-Rotter R, Trial Committees and Investigators et al (2020) Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 383(15):1436–1446. https://doi.org/10.1056/NEJMoa2024816

Article  PubMed  CAS  Google Scholar 

Cherney DZI, Zinman B, Inzucchi SE et al (2017) Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 5:610–621. https://doi.org/10.1016/S2213-8587(17)30182-1

Article  PubMed  CAS  Google Scholar 

Gerstein HC, Colhoun HM, Dagenais GR, REWIND Investigators et al (2019) Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet 394(10193):131–138. https://doi.org/10.1016/S0140-6736(19)31150-X

Article  PubMed  CAS  Google Scholar 

Tye SC, Denig P, Heerspink HJL (2021) Precision medicine approaches for diabetic kidney disease: opportunities and challenges. Nephrol Dial Transplant 36(Suppl 2):3–9. https://doi.org/10.1093/ndt/gfab045.Erratum.In:(2022)NephrolDialTransplant37:1198

Article  PubMed  Google Scholar 

Barutta F, Bellini S, Canepa S, Durazzo M, Gruden G (2021) Novel biomarkers of diabetic kidney disease: current status and potential clinical application. Acta Diabetol 58:819–830. https://doi.org/10.1007/s00592-020-01656-9.Erratum.In:(2022)ActaDiabetol.59:439-441

Article  PubMed  Google Scholar 

Ix JH, Shlipak MG (2021) The Promise of Tubule Biomarkers in Kidney Disease: A Review. Am J Kidney Dis 78:719–727. https://doi.org/10.1053/j.ajkd.2021.03.026

Article  PubMed  PubMed Central  CAS  Google Scholar 

Waijer SW, Sen T, Arnott C et al (2022) Association between TNF Receptors and KIM-1 with Kidney Outcomes in Early-Stage Diabetic Kidney Disease. Clin J Am Soc Nephrol 17:251–259. https://doi.org/10.2215/CJN.08780621

Article  PubMed  CAS  Google Scholar 

Barr ELM, Barzi F, Hughes JT et al (2018) High Baseline Levels of Tumor Necrosis Factor Receptor 1 Are Associated With Progression of Kidney Disease in Indigenous Australians With Diabetes: The eGFR Follow-up Study. Diabetes Care 41:739–747. https://doi.org/10.2337/dc17-1919

Article  PubMed  CAS  Google Scholar 

Pavkov ME, Nelson RG, Knowler WC, Cheng Y, Krolewski AS, Niewczas MA (2015) Elevation of circulating TNF receptors 1 and 2 increases the risk of end-stage renal disease in American Indians with type 2 diabetes. Kidney Int 87:812–819. https://doi.org/10.1038/ki.2014.330

Article  PubMed  CAS  Google Scholar 

Maatman RG, Van Kuppevelt TH, Veerkamp JH (1991) Two types of fatty acid-binding protein in human kidney. Isolation, characterization and localization. Biochem J 273:759–766. https://doi.org/10.1042/bj2730759

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kamijo-Ikemori A, Sugaya T, Yoshida M et al (2016) Clinical utility of urinary liver-type fatty acid binding protein measured by latex-enhanced turbidimetric immunoassay in chronic kidney disease. Clin Chem Lab Med 54:1645–1654. https://doi.org/10.1515/cclm-2015-1084

Article  PubMed  CAS  Google Scholar 

Lin J, Chen J, Wu D et al (2022) Biomarkers for the early prediction of contrast-induced nephropathy after percutaneous coronary intervention in adults: A systematic review and meta-analysis. Angiology 73:207–217. https://doi.org/10.1177/00033197211039921

Article  PubMed  CAS  Google Scholar 

Chou KM, Lee CC, Chen CH, Sun CY (2013) Clinical value of NGAL, L-FABP and albuminuria in predicting GFR decline in type 2 diabetes mellitus patients. PLoS ONE 8:e54863. https://doi.org/10.1371/journal.pone.0054863

Article  PubMed  PubMed Central  CAS  Google Scholar 

Thi TND, Gia BN, Thi HLL, Thi TNC, Thanh HP (2020) Evaluation of urinary L-FABP as an early marker for diabetic nephropathy in type 2 diabetic patients. J Med Biochem 39:224–230. https://doi.org/10.2478/jomb-2019-0037

Article  PubMed  PubMed Central  CAS  Google Scholar 

Duan XY, Liu SY, Yin DG (2021) Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: A network meta-analysis based on cardiovascular or renal outcome trials. Medicine (Baltimore) 100:e26431. https://doi.org/10.1097/MD.0000000000026431

Article  PubMed  CAS  Google Scholar 

Wei XB, Wei W, Ding LL, Liu SY (2021) Comparison of the effects of 10 GLP-1 RA and SGLT2 inhibitor interventions on cardiovascular, mortality, and kidney outcomes in type 2 diabetes: A network meta-analysis of large randomized trials. Prim Care Diabetes 15:208–211. https://doi.org/10.1016/j.pcd.2020.08.017

Article  PubMed  Google Scholar 

Zupa MF, Codario RA, Smith KJ (2021) Cost-effectiveness of empagliflozin versus weekly semaglutide as add-on therapy for Type 2 diabetes. J Comp Eff Res 10:1133–1141. https://doi.org/10.2217/cer-2021-0016

Article  PubMed  PubMed Central  Google Scholar 

Capehorn M, Hallén N, Baker-Knight J, Glah D, Hunt B (2021) Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting. Diabetes Ther 12:537–555. https://doi.org/10.1007/s13300-020-00989-6

Article  PubMed  PubMed Central  Google Scholar 

Ehlers LH, Lamotte M, Ramos MC et al (2022) The cost-effectiveness of oral semaglutide versus empagliflozin in Type 2 diabetes in Denmark. J Comp Eff Res 11:29–37. https://doi.org/10.2217/cer-2021-0169

Article  PubMed  Google Scholar 

Lingvay I, Capehorn MS, Catarig AM et al (2020) Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis. J Clin Endocrinol Metab 105:e4593–e4604. https://doi.org/10.1210/clinem/dgaa577

Article  PubMed  PubMed Central  Google Scholar 

Lui DTW, Au ICH, Tang EHM et al (2022) Kidney outcomes associated with sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists: A real-world population-based analysis. EClinicalMedicine 50:101510. https://doi.org/10.1016/j.eclinm.2022.101510

Article  PubMed  PubMed Central  Google Scholar 

Bjornstad P, Cherney DZ, Snell-Bergeon JK et al (2015) Rapid GFR decline is associated with renal hyperfiltration and impaired GFR in adults with Type 1 diabetes. Nephrol Dial Transplant 30:1706–1711. https://doi.org/10.1093/ndt/gfv121

Article  PubMed  PubMed Central  Google Scholar 

Ruggenenti P, Porrini EL, Gaspari F et al (2012) Glomerular hyperfiltration and renal disease progression in type 2 diabetes. Diabetes Care 35(10):2061–2068. https://doi.org/10.2337/dc11-2189

Article  PubMed  PubMed Central  CAS  Google Scholar 

Moriya T, Tanaka S, Sone H et al (2017) Patients with type 2 diabetes having higher glomerular filtration rate showed rapid renal function decline followed by impaired glomerular filtration rate: Japan Diabetes Complications Study. J Diabetes Complications 31:473–478. https://doi.org/10.1016/j.jdiacomp.2016.06.020

Article  PubMed  Google Scholar 

Penno G, Orsi E, Solini A, Renal Insufficiency And Cardiovascular Events (RIACE) Study Group et al (2020) Renal hyperfiltration is independently associated with increased all-cause mortality in individuals with type 2 diabetes: a prospective cohort study. BMJ Open Diabetes Res Care. https://doi.org/10.1136/bmjdrc-2020-001481

Article  PubMed  PubMed Central  Google Scholar 

Melsom T, Nair V, Schei J et al (2019) Correlation Between Baseline GFR and Subsequent Change in GFR in Norwegian Adults Without Diabetes and in Pima Indians. Am J Kidney Dis 73:777–785. https://doi.org/10.1053/j.ajkd.2018.11.011

Article  PubMed  Google Scholar 

Mann JFE, Hansen T, Idorn T et al (2020) Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1–7 randomised controlled trials. Lancet Diabetes Endocrinol 8:880–893. https://doi.org/10.1016/S2213-8587(20)30313-2

Article  PubMed  CAS  Google Scholar 

Gohda T, Kamei N, Kubota M et al (2021) Fractional excretion of tumor necrosis factor receptor 1 and 2 in patients with type 2 diabetes and normal renal function. J Diabetes Investig 12:382–389. https://doi.org/10.1111/jdi.13351

Article  PubMed  CAS  Google Scholar 

Saulnier PJ, Gand E, Velho G, SURDIAGENE Study Group et al (2017) Association of Circulating Biomarkers (Adrenomedullin, TNFR1, and NT-proBNP) With Renal Function Decline in Patients With Type 2 Diabetes: A French Prospective Cohort. Diabetes Care. https://doi.org/10.2337/dc16-1571

Article  PubMed  Google Scholar 

Nielsen SE, Reinhard H, Zdunek D et al (2012) Tubular markers are associated with decline in kidney function in proteinuric type 2 diabetic patients. Diabetes Res Clin Pract 97:71–76. https://doi.org/10.1016/

留言 (0)

沒有登入
gif